Please assess the completion status of the following clinical trial:

Trial Title: Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status (WHO) 0-2~* Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior chemotherapy received~* HER-2 overexpression 2+ or 3+ using IHC or FISH +~* Measurable disease not in a prior irradiation field (no other concurrent chemotherapy agents)~* No more than 25% of myeloproductive bone marrow irradiated (more than 4 weeks since prior radiotherapy and recovered)~* More than 6 months since prior adjuvant or neoadjuvant chemotherapy and recovered~* No prior first line chemotherapy for metastatic disease~* Endocrine therapy is allowed as adjuvant or first line treatment for metastatic disease~* Paraffin block from the primary tumor available in the research lab~* Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)~* Adequate liver (Bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl)~* Adequate cardiac function (LVEF \> 50%)~* Informed consent~Exclusion Criteria:~* Pregnant or nursing~* Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce P-450 cytochrome~* Positive pregnancy test~* Motor or sensory neuropathy \> grade 1 according to NCIC Τoxicity Criteria~* Patients with brain metastatic disease who has not been irradiated or uncontrolled brain metastatic disease after irradiation~* History of allergic reaction attributed to docetaxel~* Psychiatric illness or social situation that would preclude study compliance~* Other concurrent uncontrolled illness.~* Other invasive malignancy within the past 5 years except cured basal cell skin carcinoma and cervical carcinoma in situ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
- 2 (Type: EXPERIMENTAL): Vinorelbine + Herceptin (VHer)

Based on this trial design, predict the completion outcome and termination type (if applicable).